From Yahoo Finance: 2025-05-10 13:20:00

TransMedics Group, Inc. (TMDX) is a medical company revolutionizing organ transplantation with warm perfusion technology. The company’s OCS technology allows organs to remain alive and improve viability, with 61% of revenue coming from product sales. Despite a recent stock decline, TMDX has seen explosive growth and is expected to announce strong Q1 earnings.

The company’s long-term outlook remains promising, with a projected fair value price of $368.2 by 2030. TMDX faces limited competition, high barriers to entry, and significant growth potential in the organ transplantation market. While not among the 30 most popular stocks among hedge funds, TMDX represents a compelling long-term investment opportunity in the healthcare sector.



Read more at Yahoo Finance: TransMedics Group, Inc. (TMDX): A Bull Case Theory